

Medibio Ltd appoints highly distinguished US medical expert, Franklyn G. Prendergast, M.D., Ph.D., as a Director

Sydney, Australia 27 January 2016: Medibio Ltd (**MEB** or the **Company**), is pleased to announce the appointment of Franklyn G. Prendergast, M.D., Ph.D. to the Medibio Board of Directors. Dr Prendergast has a long and distinguished career in the US Healthcare industry and his reputation and experience within US healthcare brings tremendous credibility to the company's technology and strategy. In addition to providing the benefit of his tremendous experience, Dr Prendergast is looking forward to facilitating the commercialization of Medibio's technology for the diagnosis of mental health disorders.

Dr Prendergast is the former Chair of the Department of Biochemistry and Molecular Biology and the former Director for research at Mayo Clinic from 1989-1992. From 1989-1996, he was a member of the Board of Governors for Mayo Clinic, Rochester. From 1999-2007 inclusive, he was member of Mayo Clinic's Executive Committee, the senior most internal governance committee for the entire Mayo system. He served on Mayo Clinic's Board of Trustees continuously between 1992-2009. He was recognized as a Mayo Distinguished Investigator in 1988 and is the director emeritus, Mayo Clinic Cancer Center (1995-2006) and director emeritus for the Mayo Clinic Center for Individualized Medicine (2008-2012). Dr. Prendergast retired from Mayo Clinic in December of 2014.

Dr. Prendergast has been a member of the Eli Lilly Company Board of Directors since 1995 and he served extensively for the National Institutes of Health (NIH) on numerous study section review groups; as a charter member of the Board of Advisors for the Division of Research Grants, now the Center for Scientific Review; the National Advisory General Medical Sciences Council; the Board of Scientific Advisors of the National Cancer Institute. He held a Presidential Commission for service on the National Cancer Advisory Board. Dr. Prendergast also has served in numerous other advisory roles for the NIH. He was a member of the board of directors of the Translational Genomics Research Institute and the Infectious Disease Research Institute (IDRI).

In addition to his role on the Board of Directors of Eli Lilly, the world's largest manufacturer and distributor of medications for psychiatric and mental health-related conditions (including clinical depression, generalised anxiety disorder, bipolar disorder and schizophrenia). Dr. Prendergast currently serves on a number of boards and committees including the Board of Directors Infectious Diseases Research Institute (since 1999), Board of Directors International Medica Foundation, a nonprofit foundation committed to the development of medical products and services, (since 2007) and the Board of Visitors, College of Engineering, University of Illinois (since 2011).

In commenting on his appointment Dr Prendergast said, ***"I have been keenly watching Medibio's progress and I feel now is the right time to increase my involvement with the company. This next year could be a watershed for the company as it moves towards independent validation and regulatory approval.***

I am thrilled they are bringing an objective, evidence based test, to the field of mental illness, where none has existed before. This is a ground-breaking area and I look forward to assisting the company on its journey."

"Medibio is a pioneer in Mental Health biomarker solutions for the improvement of patient care," said Dr. Prendergast. ***"The future of Mental Health care lies in the increased precision of assessment and timely effectiveness of treatments. The Medibio Digital Mental Health Platform will be needed to realize this vision."***

About Medibio Limited

Medibio (ASX: MEB), is a medical technology company that has developed an objective test to assist in the diagnosis of depression, chronic stress, and other mental health disorders. Based on research conducted over 15 years at the University of Western Australia, this test utilizes patented circadian heart rate variability and cloud based proprietary algorithms to deliver a quantifiable measure to assist in a clinical diagnosis. Studies are currently being undertaken by Johns Hopkins University School of Medicine and Ottawa University, among others, to validate the clinical utility of the test. This will potentially enable Medibio's technology to be the first FDA approved, objective, evidence based approach to the diagnosis mental health disorders for the medical industry. The technology also provides an objective method for the assessment of stress and mental wellbeing which can be translated to the workplace stress/wellbeing market, wearable technology, and App market. Located in Sydney, NSW, Medibio is listed on the Australian Stock Exchange.

Further Information:	Website: www.medibio.com.au
Medibio Shareholder Enquiries to: Kris Knauer CEO and Director Medibio Limited kris.knauer@medibio.com.au T: +61 (0)411 885979	Medibio Media Enquiries to: Peter Taylor NWR Communications peter@nwrcommunications.com.au T: +61 (0)412 036 231